With Strong Q3 Financials, Pfizer Says It's Ready For Generic Competition To Lipitor
This article was originally published in The Pink Sheet Daily
Executive Summary
The world's largest pharma highlights sales growth of Prevnar 13, Enbrel and Lyrica, emerging markets growth, and a developing plan to sell off animal health and nutritional units.
You may also be interested in...
Can Watson Give Birth To A Pregnancy Franchise As It Helps Lay Lipitor To Rest?
Watson is progressing on a multi-year effort to diversify beyond its core U.S. generics business into branded drugs and international markets.
Countdown To Generic Lipitor: Watson Expects Pfizer To Retain 40% Market Share For Six Months
Watson, which will launch an authorized generic Nov. 30, says Pfizer is trying to get pharmacy benefit managers to give Lipitor preferred formulary status.
Countdown To Generic Lipitor: Watson Expects Pfizer To Retain 40% Market Share For Six Months
Watson, which will launch an authorized generic Nov. 30, says Pfizer is trying to get pharmacy benefit managers to give Lipitor preferred formulary status.